1. Biologics for the Treatments of Allergic Conditions: Severe Asthma.
- Author
-
Caminati M, Bagnasco D, Rosenwasser LJ, Vianello A, and Senna G
- Subjects
- Anti-Asthmatic Agents adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Asthma diagnosis, Asthma immunology, Biological Products adverse effects, Humans, Immunity, Innate drug effects, Immunity, Mucosal drug effects, Patient Selection, Respiratory Mucosa drug effects, Respiratory Mucosa immunology, Respiratory Mucosa metabolism, Severity of Illness Index, Th2 Cells drug effects, Th2 Cells immunology, Th2 Cells metabolism, Treatment Outcome, Anti-Asthmatic Agents administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Asthma drug therapy, Biological Products administration & dosage
- Abstract
By selectively targeting specific steps of the immune inflammation cascade, biologic drugs for severe asthma have substantially contributed to increase the standard of care, to reduce drug-related morbidity. and most importantly to ameliorate patients' quality of life. Upcoming molecules are going to provide a chance for severe phenotypes besides Th2 high through the interaction with epithelial and innate immunity. Some practical aspects including optimal treatment duration, the possibility of a dose treatment modulation, the place and relevance of ICS in best responders are still under debate. Long-term safety, especially when interacting with innate immunity needs to be further investigated., Competing Interests: Disclosure The authors have nothing to disclose., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF